Exhibition

ONE Platform - AI drug discovery platform

ONE Platform - AI drug discovery platform

New Drug Discovery Cloud Platform based on Artificial Intelligence


Negotiable Min Order Quantity Unit

Required Quantity
Place of Origin
South Korea
Payment Terms
Others
Production method
OBM
Shipping / Lead Time
Negotiable / Negotiable
Keyword
saas, ai drug discovery platform, ai drug development,
Category
Health , Medicines , Other Pharmaceuticals
tK Meet
tK Meet

Apply a video call to the Supplier

SEND TO SUPPLIER INQUIRY

Hits Inc.

Membership
BIZ
Country / Year Established
South Korea South Korea / 2020
Business type
Manufacturer
Verified Certificate

1

Product name ONE Platform - AI drug discovery platform Certification -
Category Health
Medicines
Other Pharmaceuticals
Material -
Keyword saas , ai drug discovery platform , ai drug development Unit Size -
Brand name - Unit Weigh -
origin South Korea Stock 10000
Supply type OBM HS code -

Product Information

ONE Platform

NewDrug Discovery Cloud Platform based on Artificial Intelligence

 

Digitalizing the new drug development process hasbecome an irresistible trend. Most pharmaceutical companies are now focusing onleveraging digital technologies to improve the odds of drug discovery anddevelopment success. Nevertheless, existing computer-aided drug discovery(CADD)software on the market does not meet the demand.

 

First of all, conventional CADD softwares (e.g. Amber,Spark, Glide, OpenEye, Chemdraw etc.) are quite expensive, but their accuracyis relatively low compared to its price. Accessibilityand user convenience are also inevitably low because conventional softwares areusually on-premise that require installation on certain devices.In addition, complex UX/UI design makes software interpretable only to a fewgroups of trained CADD researchers.

 

HITS Incorporation (HITS Inc.) has developed a newdrug discovery web platform (ONE Platform) based on its own AI technology,which brings the following key advantages to the market.

1. Improved accuracy: ONE platform significantly improves accuracy byapplying advanced AI technology. To be more specific, the hit discovery ratioof docking implemented by ONE platform was found to be more than twice as highas that of conventional docking programs.

2. User accessibility: ONE platform is developed as a cloud service(SaaS),which dramatically improves accessibility through the web. In addition, ONEplatform focuses on implementing intuitive UX/UI from the planning stage. Thisuser-friendly UX/UI of ONE platform lowers the entry barrier for experimental researcherswho are especially unfamiliar with digital drug discovery process.

 3. User convenience: ONE platform offfers all-in-one solution by includingvarious sotwares such as docking, prection of physicochemical properties,molecular dynamics simulations and so on in the single platform interface.Therefore, costumers do not need buy and install different sotwares, but simplysubscribe ONE platform having all necessary solutions. In particular, thosesoftwares are automatically updated with new features through the cloudplatform, which always provides up-to-date working environments.

With its high accuracy, accessibility, and userconvenience, One platform will be offered to users at a reasonable price on themarket, which will serve as a special competitive edge for HITS Inc.

 

Key feature 1 : Accuracy

  • More than two times higher hit discovery ratio than conventional docking
  • Keep improving as the AI technique has developed

 

Key feature 2 : Easy and intuitive execution

  • Just draw and run
  • All preprocessing is automatically done
  • Various file format (.csv, .txt, .sdf) support

Key feature 3 : Automatic 3D analysis

  • Support protein-ligand 3D interaction analysis
  • Requires no expertise in 3D structure analysis

Key feature 4 : Hit-to-Lead

  • Design promising derivatives using 3D analysis and AI predictions
  • Get hint of molecular structure modification from the 3D structure

B2B Trade

Price (FOB) Negotiable transportation Express
MOQ Negotiable Leadtime Negotiable
Payment Options Others Shipping time Negotiable

Hits Inc.

Country / Year Established
South Korea South Korea / 2020
Membership
BIZ
Business type
Manufacturer

1

President
Kim Woo Yeon
Address
124, Teheran-ro, Gangnam-gu, Seoul, Korea
Product Category
Medicines,Other Pharmaceuticals
Year Established
2020
No. of Total Employees
1-50
Company introduction

ONE Platform

: New Drug Discovery Cloud Platform based on Artificial Intelligence

 

Digitalizing the new drug development process has become an irresistible trend. Most pharmaceutical companies are now focusing on leveraging digital technologies to improve the odds of drug discovery and development success. Nevertheless, existing computer-aided drug discovery(CADD) software on the market does not meet the demand.

 

First of all, conventional CADD softwares (e.g. Amber, Spark, Glide, OpenEye, Chemdraw etc.) are quite expensive, but their accuracy is relatively low compared to its price. Accessibility and user convenience are also inevitably low because conventional softwares are usually on-premise that require installation on certain devices. In addition, complex UX/UI design makes software interpretable only to a few groups of trained CADD researchers.

 

HITS Incorporation (HITS Inc.) has developed a new drug discovery web platform (ONE Platform) based on its own AI technology, which brings the following key advantages to the market.

 

1.     Improved accuracy: ONE platform significantly improves accuracy by applying advanced AI technology. To be more specific, the hit discovery ratio of docking implemented by ONE platform was found to be more than twice as high as that of conventional docking programs.

2.     User accessibility: ONE platform is developed as a cloud service(SaaS), which dramatically improves accessibility through the web. In addition, ONE platform focuses on implementing intuitive UX/UI from the planning stage. This user-friendly UX/UI of ONE platform lowers the entry barrier for experimental researchers who are especially unfamiliar with digital drug discovery process.

3.     User convenience: ONE platform offfers all-in-one solution by including various sotwares such as docking, prection of physicochemical properties, molecular dynamics simulations and so on in the single platform interface. Therefore, costumers do not need buy and install different sotwares, but simply subscribe ONE platform having all necessary solutions. In particular, those softwares are automatically updated with new features through the cloud platform, which always provides up-to-date working environments.

With its high accuracy, accessibility, and user convenience, One platform will be offered to users at a reasonable price on the market, which will serve as a special competitive edge for HITS Inc.

Main Markets

U.S.A U.S.A

Main Product
Attached File

Related Products

Other buyers also search

Membership Grade

BUYER

Biz Pro VIP

SELLER

Biz Pro VIP
팝업닫기
Live Chat

No Data

  • There is no data to load
  • Check out the My tK > My Inquiries list.
  • After agreeing to the use of the Live Chat service, the list is printed only when there is at least one history of receiving or sending a Live Chat request.

If you have not yet agreed to use the Live Chat service,

You can use the Live Chat freely after agreeing to the use of the Live Chat service.

View more
View more